Article

Obestatin, obesity and diabetes.

Department of Physiology, Second Military Medical University, Shanghai 200433, China.
Peptides (impact factor: 2.43). 11/2008; 30(2):439-44. DOI:10.1016/j.peptides.2008.10.002 pp.439-44
Source: PubMed

ABSTRACT The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. It is well known that ghrelin plays a potential role in obesity and diabetes. Obestatin, a novel 23 amino acid amidated peptide encoded by the same gene that encodes ghrelin, was initially reported to have opposite actions to ghrelin in the regulation of food intake, emptying of the stomach and body weight. Recent work suggests that obestatin also regulate beta-cell survival and insulin secretion. The ghrelin-obestatin system is, therefore, a promising target for the developing of new drugs for the treatment of obesity and diabetes. This review summarizes the interrelationship between obestatin, obesity and diabetes.

0 0
 · 
2 Bookmarks
 · 
112 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

beta-cell survival
 
body weight
 
encodes ghrelin
 
ghrelin-obestatin system
 
higher rates
 
new drugs
 
novel 23 amino acid amidated peptide encoded
 
obesity
 
obestatin
 
potential role
 
prevalence
 
Recent work
 
review summarizes